Subtype
Esophageal Squamous Cell Carcinoma
CI-CAN-00002629ESCCExplore in graph →
212 active trials3 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002629ESCCExplore in graph →
Clinical trials
555 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (35)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06241079 | Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma | completed | — | 582 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Feb 5, 2024 | clinicaltrials |
| NCT04568200 | Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 60 | Peking Union Medical College HospitalOTHER |
| 1 |
| Jan 22, 2024 |
| clinicaltrials |
| NCT03600831 | Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 / Phase 3 | 434 | Huai'an First People's HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06184841 | HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell Carcinoma | completed | Phase 1 | 25 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT02916511 | Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma(ESO-Shanghai9) | completed | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04187352 | A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma | completed | Phase 3 | 540 | CStone PharmaceuticalsINDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT03792347 | Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus(PALACE-1) | completed | Phase 1 | 20 | Hecheng Li M.D., Ph.DOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05557955 | Identification of Breath Biomarkers in Esophageal Cancer(EC-CRT-005) | completed | — | 210 | Mian XIOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03748134 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 ) | completed | Phase 3 | 746 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 7 | Oct 24, 2023 | clinicaltrials |
| NCT05302011 | Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 28 | Peking Union Medical College HospitalOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT03888092 | Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | completed | Phase 1 / Phase 2 | 81 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT01973725 | Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy | completed | Phase 2 | 50 | Yuhong LiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02976909 | Efficacy and Safety of TPF Induction Chemotherapy for Borderline-resectable Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 46 | Yuhong LiOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT02350517 | Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer | completed | Phase 2 | 52 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT02976896 | Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment(Poetry-1) | completed | Phase 2 | 43 | Yuhong LiOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04199832 | To Compare the Effect of Different Nutritional Pathways on Improving Nutritional Status of Esophageal Cancer Patients Undergoing Chemoradiotherapy | completed | — | 156 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT04764643 | The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol Chromoendoscopy | completed | N/A | 140 | Xijing Hospital of Digestive DiseasesOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT04380480 | Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 63 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT03160209 | HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi | completed | — | 600 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03762564 | Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy(RAMOS) | completed | Phase 2 | 21 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05604950 | Surgery Versus Non-surgical Treatment for Esophageal Squamous Cell Carcinoma in Patients Older Than 70 Years | completed | — | 2 | Yongtao HanOTHER | 0 | Nov 3, 2022 | clinicaltrials |
| NCT03660449 | Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2022 | clinicaltrials |
| NCT04609813 | Esophageal cAncer Screening Trial(EAST) | completed | — | 14,597 | Changhai HospitalOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT01212822 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | completed | Phase 2 | 20 | Fox Chase Cancer CenterOTHER | 1 | Sep 7, 2022 | clinicaltrials |
| NCT03925870 | KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 45 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT04936399 | A Study of Participants With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom | completed | — | 87 | Bristol-Myers SquibbINDUSTRY | 1 | May 25, 2022 | clinicaltrials |
| NCT01137123 | Improve the Treatment of Thoracic Esophageal Cancer | completed | Phase 3 | 301 | Sun Yat-sen UniversityOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT02459457 | A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer | completed | Phase 3 | 321 | Fudan UniversityOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT04196075 | The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer(AP) | completed | Phase 3 | 30 | Chinese University of Hong KongOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT04090554 | Cytosponge™ Feasibility Study in Tanzania(CytoSCCAPE) | completed | N/A | 101 | International Agency for Research on CancerOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT02645864 | Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma | completed | Phase 1 | 12 | Peking UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT04764240 | Precisely Estimation of the Prognostic Value of Lymph Node in ESCC | completed | — | 3,700 | Shanghai Cancer Hospital, ChinaOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT02644408 | Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy | completed | Phase 3 | 184 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03116152 | Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment | completed | Phase 2 | 190 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04225364 | Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 56 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT01598077 | A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer | completed | Phase 1 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT01822613 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02890979 | Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease | completed | N/A | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 25, 2020 | clinicaltrials |
| NCT02606916 | Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer. | completed | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT03187314 | Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer | completed | Phase 2 | 25 | Hangzhou Cancer HospitalOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT02047305 | Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia | completed | N/A | 96 | Covidien, GI SolutionsINDUSTRY | 1 | May 21, 2020 | clinicaltrials |
| NCT02964455 | Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 1 | 12 | Sun Yat-sen UniversityOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT00901173 | A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya | completed | — | 372 | National Cancer Institute (NCI)NIH | 1 | Apr 24, 2020 | clinicaltrials |
| NCT02399306 | Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma | completed | Phase 3 | 222 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02649361 | Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) | completed | Phase 2 | 164 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03584308 | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | completed | Phase 2 | 110 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT01831531 | Study of S-1 in Combination With Radiotherapy in Esophageal Cancer | completed | Phase 2 | 105 | Fudan UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01591135 | A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma | completed | Phase 3 | 436 | Fudan UniversityOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT01561014 | Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 1 | 9 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Feb 5, 2024source: clinicaltrials